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Abstract
Introduction. The efficacy of dimethylaminoethanol (DMAE) derivative 7–16, substance C7070 in comparison with 
picamylon in hypertensive neuroretinopathy model in white laboratory rats was evaluated.
Materials and methods. For measuring the blood pressure, a system of noninvasive blood pressure measurement 
in small animals NIBP200 was used. Ophthalmoscopy was performed by using Bx a Neitz ophthalmoscope (Ja-
pan) and Osher MaxField 78D lens, OI-78M model. Electroretinography (ERG) was recorded in response to a 
single stimulation. Biopotentials were presented graphically on the screen with the help of BIOPAC SYSTEMS 
MP-150 with ACQKNOWLEDGE 4.2 software (USA). To assess a degree of a functional retinal disorder, the 
b/a coefficient was used.
Results and discussion. The most pronounced protective effect on the model of hypertensive neuroretinopathy is demon-
strated by C7070, which is expressed in the notable approximation to the normal eye fundus image and reaching the tar-
get values of the b/a coefficient. In the group with correction by DMAE derivative 7–16, a protective effect is observed, 
which exceeds picamilon, which is expressed in the elimination of soft and solid exudates, vein and venule plethora,  
vascular tortuosity, arterial spasm, Salus-Gunn I symptom, hemorrhages; the b/a increases significantly by 26% com-
pared to the group without correction (p < 0.05).
Conclusion. The eye fundus image and functional state of the retina are completely restored when correcting experi-
mental hypertensive neuroretinopathy with C7070 in a dose of 50 mg/kg to laboratory rats and partially restored when 
correcting with DMAE derivative 7–16 in a dose of 25 mg/kg, which in both cases exceeds the protective effect of the 
reference drug picamilon on the model of hypertensive neuroretinopathy.
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Introduction
Retinal vascular diseases lead to retinal ischemia, which, 
in turn, leads to blindness and vision impairment in peop-
le of different age groups (Rousseau et al. 2018). Ischemia 
is formed alongside hypoxia, leading to inhibiting meta-
bolic processes in the eye tissues with apoptosis of retinal 
cells (Behbehani 2007, Hayreh 2013).
Hypertensive retinopathy and neuroretinopathy in pa-
tients with hypertensive disease (HD) result from patho-
logical changes in the central retinal artery (CRA) and its 
branches, as well as from hemodynamic changes in other 
vessels of the ophthalmic artery system (Omotoso et al. 
2016, Akbar et al. 2018). Hypertensive retinopathy is re-
corded in 66.3% of patients with HD. Age, duration of 
HD and systolic blood pressure (SBP) are significant risk 
factors of retinopathy (Erden and Bicakci 2012). Hyper-
tensive retinopathy is associated with high nocturnal SBP 
(Nakano et al. 2001, Duarte et al. 2018).
Hypertensive retinopathy is fraught with complicati-
ons, including retinal arterial occlusions, optic atrophy, 
and retinal vein thrombosis (Kawasaki et al. 2013). Men 
are diagnosed with occlusion of the CRA and its bran-
ches twice as often and at a younger age than women (the 
average age being 62.4 and 65.8, respectively). Occlusion 
of the main trunk of the CRA happens in 57% of cases, 
occlusion of branches – in 38%, and cilioretinal occlu-
sions – in 5%. Acute occlusions of the retinal arteries in 
91.2% of cases occur alongside cardiovascular diseases 
(CVD) (60% – atherosclerosis and arterial hypertension 
(AH)) (Avetisov et al. 2018).
The pathogenesis of hypertensive retinopathy is still 
far from complete understanding. There are three main 
factors in the development of hypertensive retinopathy: 
constriction and increased vascular permeability of ves-
sels, and arteriosclerosis. The main factors in the develop-
ment of retinal angiopathy are disorders of general hemo-
dynamics and local endothelial dysfunction of the retinal 
vessels (Tinjust et al. 2002, Karaca et al. 2014).
By its chemical structure, DMAE is similar to choline. 
Acetylcholine (ACh), one of the main neurotransmitters, 
is formed from DMAE subsequently. In animal experi-
ments, ACh is used as a vasodilator for spasms of retinal 
arteries. In addition, DMAE has an antioxidant effect, sin-
ce it is an inhibitor of free radicals (Malanga et al. 2012).
Derivatives of DMAE, the precursors of ACh, are re-
ferred to nootropic agents: deanol aceglumate and meclo-
fenoxate. The literature data show the widespread use of 
nootropic drugs in ophthalmic practice: clinical and func-
tional studies showed faster and more stable improvement 
in visual acuity in the group of patients with chronic ocu-
lar ischemic syndrome by using choline alfoscerate (Ka-
milov et al. 2016); the use of citicoline showed a bene-
ficial effect in the treatment of amblyopia and improved 
the retinal function (Matteucci et al. 2014, Parisi et al. 
2015, Roberti et al. 2015); vinpocetine modulated meta-
bolic activity and retinal function during retinal ischemia 
(Nivison-Smith et al. 2015), etc.
Substance C7070, 3-(1H-benzimidazol-2-il)-1,2,2-tri-
methylcyclopentancarbonic acid, is a non-selective ago-
nist of imidazoline receptors type I, II. This substance is 
lipophilic (Buzov et al. 2016), thus having a half-life of 
about 4 hours when administered to rats orally, and it may 
have a prolonged effect.
Imidazoline receptors type II are widely distributed in 
brain, and their ligands may have a therapeutic potenti-
al as neuroprotective agents (Abás et al. 2017, Head and 
Mayorov 2006). In (Li 2017), Dr Jun-Xu Li reported that 
imidazoline receptors type II were new drug target for the 
treatment of neurological disorders and deserved more 
attention from researchers to translate preclinical results 
into pharmacotherapy 
Currently, the National Guidance for Ophthalmology 
has no clinical recommendations for treating hypertensive 
retinopathy, hypertensive neuroretinopathy, since the main 
therapy is aimed at treating diseases of the cardiovascular 
system. Besides, there is lack of drugs for targeted, specific 
correction of retinal ischemic damage (Shabelnikova et al. 
2014), including those that occur alongside hypertension.
In view of the above, it is important to study the pos-
sibilities of pharmacological correction of hypertensive 
neuroretinopathy in an experiment using a new DMAE 
derivative 7–16 and substance C7070.
Objective
To increase the effecacy of pharmacological correction 
of hypertensive neuroretinopathy in an experiment using 
DMAE derivative 7–16 and substance C7070.
Materials and methods
The experiments were made on Wistar male rats weighing 
225–275 g. For the study, animals were taken without ex-
ternal signs of disease and had passed the quarantine regi-
me. The ethical principles for handling laboratory animals 
were followed in compliance with “The European Con-
vention for the Protection of Vertebral Animals Used for 
Experimental and Other Scientific Purposes. CETS No. 
123”. All the manipulations in rats were carried out under 
general anesthesia with intraperitoneal (i/p) administrati-
on of chloral hydrate in a dose of 300 mg/kg of rat mass.
The following groups were included in the experiment: 
the first group (n = 10) – a control group (with i/p infusion 
of 0.9% NaCl solution in the equivalent volume for 28 
days), the second (n = 10) – a group with the simulated 
hypertensive neuroretinopathy, the third (n = 10) – with 
correction of the pathology by DMAE derivative 7–16 in 
a dose of 25 mg/kg (All-Russian scientific centre for sa-
fety of biologically active substances VNC BAV, Russia), 
the fourth (n = 10) – with the correction of the pathology 
by C7070 in a dose of 50 mg/kg (VLADMIVA Experi-
mental Plant JSC, Russia), the fifth – with the introduc-
tion of reference drug picamilon in a dose of 30 mg/kg 
(Pharmstandard-UfaVITA JSC, Russia).
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Simulation of hypertensive neuroretinopathy was per-
formed by daily i/p injection of a non-selective inhibitor 
of ΝΟ-synthases N-nitro-L-arginine methyl ester (L-NA-
ME) (Sigma, Germany) in a dose of 12.5 mg/kg in form 
of an aqueous solution for 28 days and a single increase 
in intraocular pressure (IOP) to reach 110 mmHg by ap-
plying mechanical pressure to the anterior chamber of the 
eye for 5 min on the 26th day of the experiment (Peresyp-
kina et al. 2017).
The DMAE derivative 7–16 was administered in a 
dose of 25 mg/kg/day intragastrically (i/g) 60 min before 
a daily injection of L-NAME for 28 days.
Substance C7070 was administered i/g in a dose of 50 
mg/kg once on the 26th day of the experiment, 60 minutes 
before an injection of L-NAME and an increase in IOP.
Sixty minutes before an injection of L-NAME, from 
the 22nd to the 28th days of the experiment, inclusive, pi-
camilon was daily administered i/g in a dose of 30 mg/kg 
(reference drug).
For measuring the blood pressure in rats on the tail 
on the 29th day of the experiment, a system of non-in-
vasive blood pressure measurement in small animals 
NIBP200 was used as part of BIOPAC SYSTEMS 
MP-150 complex (USA).
The eye fundi of laboratory rats were studied on 
the 29th day of the experiment (ophthalmoscope Bx a 
Neitz, Japan). To dilate eye pupils, Irifrin drops 2.5% 
were used. The ophthalmoscope was brought closer to 
the rat’s eye and a beam of light was directed at the 
eye from a distance of 0.5–2.0 cm to obtain a clear eye 
fundus image. When the fundus image was unclear, by 
turning the disk of the ophthalmoscope, a proper lens 
was selected to provide a clear images of the fundus 
details. To magnify, an Ocular Osher MaxField 78D, 
model OI-78M, was used.
For further statistical processing, the degree of chang-
es in the eye fundus caused by hypertension detected by 
ophthalmoscopy was ranked basing on the classification 
by Krasnov M.L. (Krasnov 1985) (Table 1).
The functional state of the retina was assessed with re-
spect to the correlation of amplitudes of waves b and a to 
the b/a coefficient (Sachidanandam et al. 2015). The nega-
tive a-wave generated by the outer segments of photorecep-
tors is responsible foк their functional state. The positive 
b-wave is responsible for the activity of bipolar and Muller 
cells, with the possible addition of horizontal and amacrine 
cells. For that, the animals were first kept in the dark for 30 
minutes (Zahng et al. 2013), further anesthetized (chloral 
hydrate, 300 mg/kg, v/b) and fixed on a table isolated from 
electromagnetic radiation. A silver electrode was placed on 
the cornea, a reference needle electrode EL452 was placed 
subcutaneously in the region of the skull, a grounding nee-
dle electrode EL450 was placed subcutaneously in the area 
of the base of the tail (Fig. 1). A white-flash stroboscope 
was connected to the stimulator STM200 by BIOPAC 
SYSTEM, Inc. (USA) and placed behind the animal; the 
registration of ERG was performed in response to a single 
stimulation. The evoked biopotentials were transmitted at 
a frequency of 1–1000 Hz, amplified, averaged and pre-
sented graphically on the screen by using BIOPAC SYS-
TEMS MP-150 with ACQKNOWLEDGE 4.2 software 
(USA). ERG was recorded for 0.5 sec in each rat in the 
groups. To assess a degree of development of functional 
damage to the retina, the correlation of the amplitudes of 
ERG b- and a- waves was estimated. From the ten values 
obtained in each group, the average was calculated, which 
was entered into the protocol.
The descriptive statistics were used for the data ob-
tained: the data were checked for the normality of the 
distribution. A type of distribution was determined by the 
Shapiro-Wilk criterion. In the case of normal distribution, 
the mean value (M) and the standard error of the mean (m) 
were calculated. Intergroup differences were analyzed by 
Table 1. Method of Integral Semi-quantitative Assessment of Changes in the Eye Fundus Caused by Hypertension, points.
Features of eye fundus changes Score
Norm. The optic disc (OD) is round or oval, and against the background of the fundus its colour is pale pink. The boundaries of OD are 
clear. It is located in the plane of the retina. Out of the middle of the OD come the central vessels of the retina. Retinal vessels have no 
anastomoses. Veins and arteries are straight, the caliber is uniform, with no tortuosity. The overall background is pink
0
Angiopathy. Salus-Gunn I symptom. In the eye fundus, there is "the phenomenon of chiasm", which appears due to the indentation of 
the artery in the place where it intersects with the protuberant vein. There is vein dilation on both sides of the chiasm. Guist symptom – 
dilation and corkscrew tortuosity of the venules, located around the macula lutea – occurs in case of hypertension.
1
Angiosclerosis. copper wire arteries; a sign of hypertensive angiopathy of the retina. Salus-Gunn II symptom – swellings in the area 
where the artery intersects with the  protuberant vein. 
2
Salus-Gunn III symptom – the disappearance of a vein at the intersection due to its forming an arcuate bend, dipping deep into the retina. 
Silver wire symptom. Increased vascular permeability.
3
Retinopathy. Soft exudates. Hemorrhages. In the macular zone, there may be deposits of solid star-shaped exudate. 4
Hypertensive neuroretinopathy. Obvious OD decoloration. Edema of the OD and peripapillary retina. Multiple hemorrhages and foci 
of soft exudates, indicating increasing ischemia. 
5
Figure 1. The location of electrodes during ERG in a laboratory rat.
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parametric methods (Student’s t-test) or nonparametric 
methods (Mann-Whitney’s test), depending on the type 
of distribution. Statistical analysis was performed using 
STATISTICA 10.0 software.
Results and discussion
A model of hypertensive neuroretinopathy in Wistar 
rats was used, the pathogenesis of which, among other 
things, is associated with the development of hypertensi-
on alongside the administration of L-NAME for 28 days 
(Table 2).
Due to the administratino of С7070 in a dose of 50 
mg/kg, a significant decrease in SBP by 29.2% was ob-
served, p < 0.05 compared with the group with pathology 
simulation; DBP – by 35.4%, p < 0.05 compared with the 
group with pathology simulation. The hypotensive effect 
is due to the activation of central imidazoline receptors 
type I, responsible for tonic and reflex control of the sym-
pathetic nervous system. In the groups with administering 
picamilon in a dose of 30 mg/kg; DMAE derivative 7–16 
in a dose of 25 mg/kg, no significant decrease in blood 
pressure occured.
In accordance with the study protocol, anesthesia of 
animals was performed after an increase in IOP 72 hours 
after reperfusion on the 29th day of the experiment. Then 
ophthalmoscopy was performed.
The eye fundus image in rats from the control group 
is as follows: OD is round or oval and pale pink against 
the background of the fundus. The boundaries of OD are 
clear. It is located in the plane of the retina. Out of the 
middle of the OD come the central vessels of the retina. 
Retinal vessels  have no anastomoses. Veins and arteries 
are straight, the caliber is uniform, with no tortuosity. The 
overall background is pink.
The fundus image in rats with stimulated hyperten-
sive neuroretinopathy is as follows: OD is edematous, 
increased, edema extends to the retina. The boundaries of 
OD are unclear. There are foci of soft exudate, indicating 
an increase in ischemia. The veins are plethoric, twisted 
on the periphery. The arteries are narrowed. The retina 
is ischemic. Salus-Gunn I-III symptom. In single cases, 
there were foci of solid exudates. Hemorrhages.
In the group with correction by DMAE derivative 7–16 
in a dose of 25 mg/kg, the following fundus image was ob-
served: OD is round, non-edematous, pale pink, is located 
in the plane of the retina, the boundaries are clear. The 
veins and arteries are straight, the caliber is uniform, with 
no tortuosity. The overall background is pink (Fig. 2A).
In the group with correction of pathology by 7070, the 
fundus image shown in Figure 2B was observed: OD is 
round, pale pink, the boundaries are clear. The veins and 
arteries are straight, of the same caliber. The overall back-
ground is pink.
In the group with correction by picamilon in a dose of 
30 mg/kg, the following ophthalmoscopic picture was ob-
served: OD is not edematous, pink, with clear boundaries. 
The veins and arteries are mostly straight, sometimes tortu-
os, the caliber of the vessels is uneven, approximately 2:1 
(veins : arteries). In single cases, arteriovenous crossings 
were observed. The overall background is pink (Fig. 3).
Table 2. Influence of DMAE Derivative 7-16, C7070 and Picamilon on Blood Pressure Indices in Rats on the 29th Day of the Ex-
periment Alongside Administration of N-nitro-L-arginine methyl ether (M±m; n=10), mm Hg.
Experimental groups SBP (mm Hg) DBP (mm Hg)
Control 139.2±5.4 104.2±4.7
Hypertensive neuroretinopathy simulation 204.8±10.0* 164.2±5.9*
Correction by DMAE derivative 7-16, 25 mg/kg 202.8±10.1* 164.0±6.9*
Correction by C7070, 50 mg/kg 145.1±7.1у 106.0±5.1у
Correction by picamilon, 30 mg/kg 200.0±9.4* 158.0±7.8*
Note: SBP – systolic blood pressure, DBP – diastolic blood pressure. * – p < 0.05 in comparison to the control group; у – p < 0.05 in comparison to 
the group with pathology simulation.
Figure 2. An example of an ophthalmoscopic picture in Wistar rats with correction of hypertensive neuroretinopathy by DMAE 
derivative 7–16 (A), C7070 (B).
A B
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The results of the integrated semi-quantitative assess-
ment of the fundus state in the experimental groups are 
presented in Table 3.
Thus, the results of ophthalmoscopy and integrated 
semi-quantitative assessment of the fundus state on the 
model of hypertensive neuroretinopathy showed that the 
most effective was the correction by DMAE derivative 
7–16 in a dose of 25 mg/kg, as well as by C7070 in a dose 
of 50 mg/kg, exceeding the reference drug picamilon in a 
dose of 30 mg/kg.
The influence of DMAE derivative 7–16, C 7070 on 
the electrophysiological state of the retina when correct-
ing hypertensive neuroretinopathy in comparison to pi-
camilon was estimated using the b/a coefficient, the val-
ues of which are presented in Table 4.
In the group with pathology simulation, the b/a co-
efficient is by 27% less (p < 0.05) compared to the con-
trol. In the group with correction by DMAE 7–16 de-
rivative, the b/a coefficient increases by 26% compared 
to the group without correction (p < 0.05). Alongside 
the correction by C7070, the b/a coefficient increases 
by 32% compared to the group without correction (p < 
0.05) and reaches the target values. In case of correcting 
by picamilon in a dose of 30 mg/kg, the b/a coefficient 
increases by 21% compared to the group without cor-
rection (p < 0.05) and is significantly different from the 
control group, which does not allow to talk about the 
complete restoration of the electrophysiological activity 
of the retina.
An increase in the value of the b/a coefficient indicates 
the preservation of the electrophysiological function of 
the retina after the simulation of hypertensive neuroreti-
nopathy against the background of the correction.
The changes in b/a in the animals with simulated hy-
pertensive neuroretinopathy were caused by both a sharp 
decrease in the amplitude of b-wave and a slight decrease 
in the amplitude of a-wave, which indicates an impared 
electrophysiological function of both neurons of the nu-
clear retinal layers and photoreceptors (Fig. 4). When 
correcting with the pharmacological agents under study, 
an increase in the positive b-wave was observed, due to 
which the b/a coefficient increased (Fig. 5).
Thus, the most pronounced correction of electrophys-
iological changes in the retina against the background of 
the simulated hypertensive neuroretinopathy, based on 
the values of the b/a coefficient, was recoreded for C7070 
and exceeded correction by picamilon. In the group with 
the administration of DMAE derivative 7–16 in a dose of 
25 mg/kg, the target values of the b/a coefficient were not 
achieved, but the mean value was higher than in the group 
with correction by picamilon.
Conclusions
The results of the complex assessment, including ophthal-
moscopy, integral semi-quantitative assessment of  chan-
ges in the eye fundus, assessment of the electrophysiolo-
gical state of the retina on the 29th day of the experiment, 
revealed that the most pronounced protective effect of 
the tested pharmacological agents on the model of hyper-
tensive neuroretinopathy was demonstrated by substan-
ce C7070 in a dose of 50 mg/kg, which is expressed in 
the notable approximation to the normal fundus image, 
electroretinogram and reaching the target values of the 
b/a coefficient, exceeding by 32% the results in the group 
without correction (p < 0.05).
When correcting by DMAE derivative 7–16 in a dose 
of 25 mg/kg, the protective effect was observed, excee-
ding that from picamilon in a dose of 30 mg/kg, resulting 
in the elimination of foci of soft and solid exudates, which 
indicated increasing ischemia, the plethora of veins and 
venules, vessel tortuosity, and arteries spasm. The retina 
Table 3. Influence of DMAE Derivative 7–16, C7070 and Pi-
camilon on the Results of Integrated Assessment of Changes in 




Hypertensive neuroretinopathy simulation 4.9±0.1*
Correction by DMAE derivative 7-16, 25 mg/kg 0.3±0.5у
Correction by C7070, 50 mg/kg 0.2±0.3у
Correction by picamilon, 30 mg/kg 1.0±0.2*у
Note: * – p < 0.05 in comparison to the control group; у – p < 0.05 in 
comparison to the group with pathology simulation.
Table 4. Influence of DMAE Derivative 7-16, C7070 and Pi-
camilon on the Value of the b/a Coefficient When Correcting 
Hypertensive Neuroretinopathy (M±m; n=10), R.U.
Experimental groups b/a
Control 2.60±0.07у
Hypertensive neuroretinopathy simulation 1.90±0.08*
Correction by DMAE derivative 7-16, 25 mg/kg 2.40±0.06 у  
Correction by C7070, 50 mg/kg 2.50±0.11у
Correction by picamilon, 30 mg/kg 2.30±0.10*у
Note: * – p < 0.05 in comparison to the control group; у – p < 0.05 in 
comparison to the group with pathology simulation.
Figure 3. The eye fundus of the rat with correction of hyperten-
sive neuroretinopathy by picamilon.
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Figure 4. Electroretinograms of Wistar rats. A control group B 
with simulated hypertensive neuroretinopathy.
Figure 5. Electroretinograms of Wistar rats: A: correction of hy-
pertensive neuroretinopathy by DMAE derivative 7–16, 25 mg/
kg. B: correction of hypertensive neuroretinopathy by picami-
lon, 30 mg/kg. C: correction of hypertensive neuroretinopathy 
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was not ischemic. Salus-Gunn I symptom and hemorrha-
ges were eliminated. The caliber of the retinal vessels was 
aligned. There was a significant increase in the amplitude 
of b-wave, due to which the b/a coefficient significantly 
increased by 26% compared to the group without correc-
tion (p < 0.05).
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